The AAAAI Foundation and Phil and Barbara Lieberman and Friends Lecture: Investing Together in Our Future (9th year)

2521 Beyond LEAP: NIAID-Supported Studies in Peanut Allergy Prevention
Saturday, February 25, 2023
Convention Center, Ballroom Level, Stars at Night B1, 12:30 pm – 1:45 pm
Lecturer: Gideon Lack, MD
LEAP Participants: Living with AD Libitum Peanut Consumption

The AAAAI Foundation and Phil and Barbara Lieberman and Friends Lectureship: Investing Together in Our Future will be presented by Gideon Lack, MD on Saturday, February 25th during in session 2521 Beyond LEAP: NIAID-Supported Studies in Peanut Allergy Prevention in Convention Center, Ballroom Level, Stars at Night B1, 12:30 pm – 1:45 pm (presentation 1:35pm)

Phil Lieberman, MD FAAAAI

Phil Lieberman is a Clinical Professor of Pediatrics and Internal Medicine in the Allergy/Immunology division of the University Of Tennessee College Of Medicine in Memphis TN. He is a graduate of the University Of Tennessee College Of Medicine and did his residency in Internal Medicine at this institution and completed his Allergy-Immunology Fellowship at Northwestern University Medical school. Upon completion of his fellowship he returned to the University of Tennessee to found the Allergy-Immunology Division in the Department of Medicine. He is a past president of the AAAAI.

Gideon Lack, MD

Gideon Lack is Professor of Paediatric Allergy at King’s College London and Head of the Children’s Allergy Clinical Academic Group at King’s Health Partners Institute of Women and Children’s Health at Evelina London, Guy’s & St. Thomas’ NHS Foundation Trust. He studied medicine at Oxford University before training as a Paediatrician in New York and specialised in Allergy at National Jewish Center in Denver, Colorado. He was Professor of Paediatric
Allergy and Immunology at Imperial College London where he worked for 12 years before moving to King’s College London in 2006.

His research focuses on the prevalence of food allergies in children and the relationship between food allergies, eczema, and asthma. He works on novel immune-modulatory treatments for food allergies and on developing new strategies to prevent the development of allergies and asthma in children and adults.

The LEAP (Learning Early About Peanut allergy) study, published in the New England Journal of Medicine (2015) showed that early consumption of peanuts in atopic infants reduces the development of peanut allergy by >80%. In 2016-17 these findings were translated into changes in public health policy in the USA (National Institute of Allergy and Infectious Diseases, a division of the US Department of Health and Human Services, Addendum Guidelines for the Prevention of Peanut Allergy in the United States) and Australia. Recommendations to introduce peanut in children 4-6 months of age at high risk of developing peanut allergy.

Prof. Lack serves as a Member of Scientific Advisory Board at DBV Technologies S.A. He is a Member of the British Medical Association (BMA), The European Academy of Allergology and Clinical Immunology (EAACI) and the Royal College of Paediatrics and Child Health and a Fellow of The Academy of Medical Sciences.